ZYDUS LIFESCIENCES Financial Statement Analysis
|
||
|
The Revenues of ZYDUS LIFESCIENCES have increased by 13.40% YoY .
The Earnings Per Share (EPS) of ZYDUS LIFESCIENCES has increased by 98.04 % YoY. |
||
| REVENUES |
| OPERATING MARGIN |
| PROFIT AFTER TAX |
| EPS |
| ROCE |
ZYDUS LIFESCIENCES Last 5 Annual Financial Results
[BOM: 532321|NSE : ZYDUSLIFE]
| Consolidated | Mar2024 | Mar2023 | Mar2022 | Mar2021 | Mar2020 |
|---|---|---|---|---|---|
| Revenues | ₹19,547 Cr | ₹17,237 Cr | ₹15,110 Cr | ₹14,404 Cr | ₹14,253 Cr |
| Expenses | ₹14,248 Cr | ₹13,666 Cr | ₹11,935 Cr | ₹11,018 Cr | ₹11,473 Cr |
| Operating Profit (Excl OI) | ₹5,299 Cr | ₹3,572 Cr | ₹3,175 Cr | ₹3,385 Cr | ₹2,780 Cr |
| Other Income | ₹369 Cr | ₹475 Cr | ₹391 Cr | ₹75 Cr | ₹117 Cr |
| Interest | ₹81 Cr | ₹130 Cr | ₹127 Cr | ₹186 Cr | ₹342 Cr |
| Depreciation | ₹764 Cr | ₹723 Cr | ₹713 Cr | ₹670 Cr | ₹697 Cr |
| Profit Before Tax | ₹4,809 Cr | ₹2,590 Cr | ₹2,838 Cr | ₹2,399 Cr | ₹1,495 Cr |
| Profit After Tax | ₹3,831 Cr | ₹2,002 Cr | ₹2,326 Cr | ₹2,206 Cr | ₹1,176 Cr |
| Consolidated Net Profit | ₹3,860 Cr | ₹1,960 Cr | ₹4,487 Cr | ₹2,134 Cr | ₹1,177 Cr |
| Earnings Per Share (Rs) | ₹38.36 | ₹19.37 | ₹43.82 | ₹20.84 | ₹11.49 |
| PAT Margin (%) | 10.10 | 5.90 | 7.87 | 7.64 | 8.25 |
| ROE(%) | 20.52 | 11.60 | 15.51 | 18.88 | 11.32 |
| ROCE(%) | 24.90 | 13.64 | 15.30 | 14.38 | 10.02 |
| Total Debt/Equity(x) | 0.04 | 0.07 | 0.25 | 0.35 | 0.77 |
Key Financials |
||
| Market Cap | : | ₹ 84,264.2 Cr |
| Revenue (TTM) | : | ₹ 22,247.4 Cr |
| Net Profit(TTM) | : | ₹ 4,591.8 Cr |
| EPS (TTM) | : | ₹ 45.6 |
| P/E (TTM) | : | 18.4 |
| Industry Peers & Returns | 1W | 1M | 1Y |
| ZYDUS LIFESCIENCES | -4.6% | -5.6% | -12.2% |
| SUN PHARMACEUTICAL INDUSTRIES | -1.7% | 5.5% | 5.4% |
| DIVIS LABORATORIES | -5.2% | -4.6% | 49% |
| CIPLA | -4.2% | -2.4% | -3.8% |
| TORRENT PHARMACEUTICALS | 1.6% | 8.4% | 26.9% |
| DR REDDYS LABORATORIES | -5.5% | -3.4% | -9.4% |
| MANKIND PHARMA | -3.2% | 3.9% | 5% |
| LUPIN | -1.7% | -4.3% | 22.8% |
| AUROBINDO PHARMA | -3.5% | 0.3% | -2.8% |
ZYDUS LIFESCIENCES Revenues
[BOM: 532321|NSE : ZYDUSLIFE]
| Y-o-Y | 13.40 % |
| 5 Yr CAGR | 8.22 % |
| Years | Revenues | % Change | |
|---|---|---|---|
| Mar2024 | ₹19,547 Cr | 13.40 | |
| Mar2023 | ₹17,237 Cr | 14.08 | |
| Mar2022 | ₹15,110 Cr | 4.90 | |
| Mar2021 | ₹14,404 Cr | 1.06 | |
| Mar2020 | ₹14,253 Cr | - | |
ZYDUS LIFESCIENCES Operating Profit
[BOM: 532321|NSE : ZYDUSLIFE]
| Y-o-Y | 48.35 % |
| 5 Yr CAGR | 17.50 % |
| Years | Operating Profit | % Change | |
|---|---|---|---|
| Mar2024 | ₹5,299 Cr | 48.35 | |
| Mar2023 | ₹3,572 Cr | 12.51 | |
| Mar2022 | ₹3,175 Cr | -6.22 | |
| Mar2021 | ₹3,385 Cr | 21.76 | |
| Mar2020 | ₹2,780 Cr | - | |
| Operating Margins | |
|---|---|
| Y-o-Y | 30.84 % |
| 5 Yr CAGR | 8.57 % |
| Years | Operating Margin% | % Change | |
|---|---|---|---|
| Mar2024 | 27.11% | 30.84 | |
| Mar2023 | 20.72% | -1.38 | |
| Mar2022 | 21.01% | -10.60 | |
| Mar2021 | 23.5% | 20.45 | |
| Mar2020 | 19.51% | - | |
ZYDUS LIFESCIENCES Profit After Tax
[BOM: 532321|NSE : ZYDUSLIFE]
| Y-o-Y | 96.88 % |
| 5 Yr CAGR | 34.58 % |
| Years | Profit After Tax | % Change | |
|---|---|---|---|
| Mar2024 | ₹3,860 Cr | 96.88 | |
| Mar2023 | ₹1,960 Cr | -56.31 | |
| Mar2022 | ₹4,487 Cr | 110.32 | |
| Mar2021 | ₹2,134 Cr | 81.34 | |
| Mar2020 | ₹1,177 Cr | - | |
| PAT Margins | |
|---|---|
| Y-o-Y | 71.19 % |
| 5 Yr CAGR | 5.19 % |
| Years | PAT Margin(%) | % Change | |
|---|---|---|---|
| Mar2024 | 10.1 % | 71.19 | |
| Mar2023 | 5.9 % | -25.03 | |
| Mar2022 | 7.87 % | 3.01 | |
| Mar2021 | 7.64 % | -7.39 | |
| Mar2020 | 8.25 % | - | |
ZYDUS LIFESCIENCES Earnings Per Share (EPS)
[BOM: 532321|NSE : ZYDUSLIFE]
| Y-o-Y | 98.04 % |
| 5 Yr CAGR | 35.17 % |
| Years | EPS | % Change | |
|---|---|---|---|
| Mar2024 | ₹38 | 98.04 | |
| Mar2023 | ₹19 | -55.80 | |
| Mar2022 | ₹44 | 110.27 | |
| Mar2021 | ₹21 | 81.38 | |
| Mar2020 | ₹11 | - | |
ZYDUS LIFESCIENCES Return on Capital Employed (ROCE)
[BOM: 532321|NSE : ZYDUSLIFE]
| Y-o-Y | 82.55 % |
| 5 Yr CAGR | 25.55 % |
| Years | ROCE | % Change | |
|---|---|---|---|
| Mar2024 | 24.9% | 82.55 | |
| Mar2023 | 13.64% | -10.85 | |
| Mar2022 | 15.3% | 6.40 | |
| Mar2021 | 14.38% | 43.51 | |
| Mar2020 | 10.02% | - | |
ZYDUS LIFESCIENCES Share Price vs Sensex
| Current Share Price | : | ₹837.5 |
| Current MarketCap | : | ₹ 84,264.2 Cr |
| Updated EOD on | : | Apr 07,2025 |
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| ZYDUS LIFESCIENCES | -4.6% |
-5.6% |
-12.2% |
| SENSEX | -5.5% |
0.2% |
-1% |
ZYDUS LIFESCIENCES related INDICES
| BSE Indices | 1W | 1M | 1Y |
|---|---|---|---|
| BSE ALLCAP | NA | 7% | 4.8% |
| BSE LARGEMIDCAP | -2.9% | 4.2% | 0.9% |
| BSE 500 SHARIAH | -4.7% | 1.4% | -5.7% |
| BSE HEALTHCARE | -5.2% | 1.8% | 10.7% |
| BSE DIVIDEND STABILITY INDEX | -5.5% | 1% | -7.5% |
| NSE Indices | 1W | 1M | 1Y |
|---|---|---|---|
| NIFTY MIDSMALL INDIA CONSUMPTION | -3.9% | 1.9% | 9.9% |
| NIFTY ALPHA QUALITY LOW-VOLATILITY 30 | -4.1% | 1.8% | -6.3% |
| NIFTY ALPHA LOW-VOLATILITY 30 | -4.3% | 1.5% | -9.2% |
| NIFTY HEALTHCARE INDEX | -4.6% | 2.5% | 7.3% |
| NIFTY100 QUALITY 30 | -4.9% | 0.1% | -3.8% |
You may also like the below Video Courses
FAQ about ZYDUS LIFESCIENCES Financials
How the annual revenues of ZYDUS LIFESCIENCES have changed ?
The Revenues of ZYDUS LIFESCIENCES have increased by 13.40% YoY .
How the Earnings per Share (EPS) of ZYDUS LIFESCIENCES have changed?
The Earnings Per Share (EPS) of ZYDUS LIFESCIENCES has increased by 98.04 % YoY .
Check out Intrinsic Value of Peers of ZYDUS LIFESCIENCES
Compare Stock Analytics of Peers of ZYDUS LIFESCIENCES
SUN PHARMACEUTICAL INDUSTRIES LTD vs DIVIS LABORATORIES LTD vs CIPLA LTD
TORRENT PHARMACEUTICALS LTD vs DR REDDYS LABORATORIES LTD vs
SUN PHARMACEUTICAL INDUSTRIES LTD vs DIVIS LABORATORIES LTD vs CIPLA LTD
TORRENT PHARMACEUTICALS LTD vs DR REDDYS LABORATORIES LTD vs
